A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2018
At a glance
- Drugs SHR 0302 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 25 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 29 Apr 2015 New trial record